Disease Areas of Focus

We are committed to fully exploring the potential of ibrutinib's mechanism of action

One of our primary goals at Pharmacyclics is to fully research the potential of BTK inhibition for patients. We have built one of the most robust clinical oncology development programs for a single molecule in the industry to help us accomplish that goal. There are approximately 130 ongoing ibrutinib clinical trials, with 30 company-sponsored trials, 14 of which are in Phase 3, and roughly 100 investigator-sponsored trials and external collaborations that are active around the world. Preclinical and clinical studies are currently ongoing in the following disease areas:

Chronic Lymphocytic Leukemia (CLL)

A rare, hard-to-treat and slow-growing blood cancer that most commonly arises from B-cells, a type of white blood cell (lymphocyte) that originates in the bone marrow, and is the most common adult leukemia.

Small Lymphocytic Lymphoma (SLL)

A slow-growing lymphoma that is biologically similar to CLL, in which too many immature white blood cells cause lymph nodes to become larger than normal.

Mantle Cell Lymphoma (MCL)

An aggressive form of blood cancer that arises from B cells. MCL is more prevalent among men than women and most patients are in their mid-60s at diagnosis.

Waldenström’s Macroglobulinemia (WM)

A rare, indolent type of B-cell lymphoma. In the U.S., there are approximately 1,000 to 1,500 new cases of WM each year and the average age at diagnosis is 60 to 70 years of age.

Marginal Zone Lymphoma (MZL)

A rare, slow-growing cancer that affects the lymph nodes and other areas of the body.

Chronic Graft-Versus-Host- Disease (cGVHD)

A severe, potentially life-threatening consequence of an allogeneic stem cell or bone marrow transplant where the recipient’s tissues are attacked by bone marrow donor’s immune cells.

Diffuse Large B-cell Lymphoma (DLBCL)

An aggressive B-cell lymphoma and the most common subtype of Non-Hodgkin’s Lymphoma, which is a cancer that starts in white blood cells
(lymphocytes) that are part of the body’s immune system.

Follicular Lymphoma (FL)

The most common subtype of slowgrowing (indolent) Non-Hodgkin’s Lymphoma. It is often slow growing, but hard to cure. Over time, about one-third of FL cases turn into a fastgrowing form of DLBCL.

Solid Tumors

Cancers can often occur in the form of a lump called a tumor. Malignant tumors can occur in many different locations throughout the body, including the gastrointestinal and genitourinary regions where we have ongoing clinical studies.

Our Science

Our science extends beyond the borders of our laboratories. We work to discover new therapies to advance the standard of care and strive to help patients rediscover the Magic of Normal. 

Areas of Study

We are committed to fully exploring the potential of ibrutinib as a therapy for additional diseases with great unmet medical need.